Sumitomo Mitsui DS Asset Management Company Ltd Increases Position in Medtronic PLC $MDT

Sumitomo Mitsui DS Asset Management Company Ltd raised its position in Medtronic PLC (NYSE:MDT) by 4.2% during the fourth quarter, Holdings Channel reports. The firm owned 176,033 shares of the medical technology company’s stock after buying an additional 7,075 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Medtronic were worth $16,910,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Medtronic by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 128,961,343 shares of the medical technology company’s stock worth $12,388,027,000 after acquiring an additional 1,888,381 shares in the last quarter. State Street Corp grew its stake in shares of Medtronic by 1.0% in the third quarter. State Street Corp now owns 60,460,537 shares of the medical technology company’s stock worth $5,800,550,000 after acquiring an additional 625,992 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Medtronic by 0.9% in the third quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company’s stock worth $2,044,637,000 after acquiring an additional 192,410 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Medtronic by 0.5% in the third quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company’s stock worth $2,008,278,000 after acquiring an additional 98,220 shares in the last quarter. Finally, Raymond James Financial Inc. grew its stake in shares of Medtronic by 3.0% in the third quarter. Raymond James Financial Inc. now owns 11,203,865 shares of the medical technology company’s stock worth $1,067,055,000 after acquiring an additional 327,899 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Price Performance

Shares of NYSE:MDT opened at $77.64 on Thursday. The company has a 50-day simple moving average of $87.64 and a 200-day simple moving average of $94.55. Medtronic PLC has a one year low of $77.16 and a one year high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The stock has a market capitalization of $99.68 billion, a price-to-earnings ratio of 21.63, a PEG ratio of 1.85 and a beta of 0.62.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. During the same period in the prior year, the company earned $1.38 earnings per share. The business’s revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts predict that Medtronic PLC will post 5.57 EPS for the current year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.7%. The ex-dividend date of this dividend was Friday, March 27th. Medtronic’s dividend payout ratio is presently 79.11%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on MDT. Truist Financial lowered their target price on shares of Medtronic from $103.00 to $95.00 and set a “hold” rating for the company in a research note on Wednesday, April 15th. Weiss Ratings downgraded shares of Medtronic from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, April 21st. Leerink Partners reiterated an “outperform” rating and set a $119.00 target price on shares of Medtronic in a research note on Tuesday, March 10th. Needham & Company LLC reiterated a “buy” rating and set a $120.00 target price on shares of Medtronic in a research note on Thursday, March 26th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. Fifteen analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $107.80.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.26% of the company’s stock.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Regulatory and clinical progress for electrophysiology assets: Medtronic highlighted momentum for the Affera electrophysiology platform and noted an FDA Breakthrough Device designation, a potential catalyst for commercial adoption in arrhythmia treatment. Medtronic highlights Affera momentum and FDA Breakthrough Device designation
• Positive Sentiment: CE mark granted for VitalFlow ECMO transport technology, validating a commercial pathway in critical?care transport and supporting incremental device revenue opportunities. Medtronic wins CE mark for VitalFlow ECMO transport tech
• Positive Sentiment: Strategic investment signaling continued partnership activity: Medtronic fulfilled a $20M financing commitment to Orchestra BioMed under an existing collaboration to support the BACKBEAT pivotal trial for AVIM therapy, showing Medtronic’s continued investment in outside innovation and potential future pipeline upside (amount is modest relative to MDT’s scale). Orchestra BioMed receives $20M payment from Medtronic
• Neutral Sentiment: Related financing news for Orchestra: Ligand made a $15M tranche to Orchestra under a royalty?based financing agreement; combined with Medtronic funding this brings additional capital to Orchestra but has limited direct impact on Medtronic’s near?term fundamentals. Orchestra BioMed receives $15M from Ligand
• Neutral Sentiment: Market research & sentiment pieces are parsing whether Wall Street is bullish or bearish on MDT, reflecting divergent analyst takes rather than a single consensus driver. That debate is keeping trading choppy. Medtronic stock outlook: Is Wall Street bullish or bearish?
• Negative Sentiment: Near?term selling pressure and price weakness: Market reports note MDT shares have pulled back amid profit?taking and skepticism from some analysts about growth versus the guidance range; that has pressured the stock despite earnings that modestly beat estimates. Medtronic (MDT) Stock Sinks As Market Gains: Here’s Why
• Negative Sentiment: Mixed analyst reactions and a small trim to fair?value estimates: Some research shops have slightly lowered targets or expressed caution on guidance execution and the timing of new product rollouts, creating downward pressure on the stock. How The Medtronic (MDT) Story Is Shifting As Guidance Meets Mixed Wall Street Views

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).